ERBB2 and neoplasm: In the IMPACT study, in which biological efficacy was assessed using the nuclear proliferation antigen Ki67, suppression of Ki67 was significantly greater in HER2− tumours compared to those overexpressing HER2 following either tamoxifen or anastrozole, but not the combination treatment (Dowsett et al. 2005a).